Korea University Medical Center (Director Eul-sik Yoon) announced that it will participate in ‘BIO KOREA 5’, which will be held at COEX in Seoul for three days from Wednesday, May 10th to Friday, May 12th.
Korea University Medical Center is a comprehensive medical institution with outstanding capabilities in medical education, medical research, and clinical trials. Its affiliated educational institutions include the School of Medicine, the Graduate School of Public Health, and the Graduate School of Clinical Dentistry. The medical institutions include Anam, Guro, and Ansan Hospital, and research-oriented campuses such as Jeongneung MediScience Park and Goyeong Campus. Korea University Medical Center has selected ‘research’ as the institution’s future growth engine and is pursuing various efforts to develop cutting-edge medical technology based on data and experience accumulated in clinical practice, commercialize the technology, and apply it to the medical field. To this end, Korea University Medical Center opened Medi Science Park and Goyoung Campus, a cutting-edge innovative research platform, in 2021.
MediScience Park was created with the core concept of a convergence R&D hub where organic industry-academia cooperation takes place from the planning stage. In particular, we will build cutting-edge biosafety research facilities such as ABSL3 and BSL3 that can study high-risk viruses, as well as animal testing facilities and the latest research equipment, and make them available to external industries and research institutes for open use through free and creative joint research. Innovation was encouraged to take place actively.
Based on this environment, Korea University Medical Center signed an agreement with SK Bioscience on infectious disease research and development of a next-generation vaccine platform and is conducting joint research worth about KRW 3 billion over 50 years, and is expected to produce tangible results in the near future. there is. MediScience Park already has anticancer new drug companies with their own GMP (Good Manufacturing Practices) manufacturing facilities, as well as promising healthcare companies focusing on medical big data, incurable disease and gene treatments, digital treatments, electronic medicine, and smart diagnostic technology development. Six companies and startups settled in.
Based on the infrastructure of MediScience Park, a natural research environment, the synergy between these institutions and the faculty and researchers of Korea University Medical Center is expected to further accelerate, and by expanding the occupancy of up to 30 institutions within the park, convergence through industry-academia cooperation will be achieved. We plan to further grow the research pie, and the ‘Clinical Research Support Center’ will help domestic medical devices advance overseas based on the ‘ISO 14155’ certification that complies with the European Medical Device Act, which Korea University Medical Center obtained for the first time as a general hospital in the world. there is.
Cheongdam Goyeong Campus, located in a strategic location in Gangnam, Seoul, also meets the requirements for optimal industry-academia-research cooperation. The ‘Medical Imaging Center’, where medical image analysis and research is conducted based on the cloud-based hospital information system (P-HIS), and a multinational home healthcare company that is receiving a lot of attention as an alternative in the aging era are located, providing a diverse spectrum of collaboration with the industry. Expectations are high for it to be shown.
In addition, Korea University Medical Center is the only single institution with multiple research-oriented hospitals (Anam and Guro Hospitals), one of only 10 in Korea, and is leading the operation of major national research projects. The K-MASTER project group, which is developing precision medicine-based cancer diagnosis and treatment based on government investment of approximately 5 billion won over 430 years, recently achieved the achievement of genome profiling of 1 cancer patients, and Guro Hospital It was selected as the overall organization for the ‘intelligence and big data-based innovative medical technology advancement project’ and is leading detailed research in six fields worth approximately 2028 billion won by 358.
In addition to maintaining hardware to become a top-notch research-centered institution, Korea University Medical Center established a research strategy headquarters to select and advance ’10 leading technologies’ to preemptively implement future medicine through strategic research planning. The 10 leading technologies are ▲Cancer Precision Medicine ▲Cloud-hospital Information System ▲Liquid Biopsy ▲AI-based Drug Design ▲Patient Patient-on-a-chip ▲Genome Editing ▲Human Microbiome ▲3D Organ Printing ▲Wearable Soft Robot ▲Memory It consists of memory editing.
This year, Bio Korea Korea University Medical Center Public Relations Center will hold an excellent technology briefing session (KU Medicine with H+TLO, Innovation Spark: Showcase of Tomorrow’s Health Solutions) to share the latest issues related to biomedical science. At this technology briefing session, technologies held by healthcare technology commercialization organizations (TLO, Technology Licensing Offices) such as Korea University Medical Center, Kangwon National University Industry-Academic Collaboration Foundation, Pusan National University Hospital, Bundang Cha Hospital, and Seoul National University Bundang Hospital will also be introduced. In addition, an opportunity will be prepared to introduce excellent technologies owned by Korea University Medical Center faculty start-ups. There will also be on-site consultation time with researchers at the Korea University Medical Center public relations booth.
The technologies that will be introduced at the excellent technology briefing session are largely 5 technologies in the pharmaceutical and bio fields and 6 technologies in the medical device field. In the medical bio field, ▲non-alcoholic fatty liver diagnostic marker using a combination of microRNAs ▲anticancer virus using recombinant herpesvirus ▲composition for treating bone diseases containing MSCs with excellent osteogenic differentiation ability ▲introduction and development of cognitive function improvement based on cannabinoid derivatives ▲drugs This includes ocular injectable microgels as delivery systems and hydrogels containing them.
In the field of medical devices, ▲AI-based cardioembolic cerebral infarction diagnosis assistance using simple chest imaging images ▲devices that measure abnormalities by measuring minute changes in muscles ▲social anxiety treatment system based on video conference images ▲evaluation methods for head impulse tests and There are devices ▲ a method of providing information for diagnosing castration-resistant prostate cancer and a kit for diagnosing castration-resistant prostate cancer therefor ▲ an automatic flow control method for medical use and a device using the same.
Start-up companies include ▲Andante FM Co., Ltd. ▲STARCC LAB ▲GR Pharm Co., Ltd. ▲Myotech Science Co., Ltd. ▲Huser Cardian Co., Ltd.
An official at Korea University Medical Center said, “We are conducting massive convergence research differentiated from existing medical institutions through the ‘5 CAMPUS system’, which combines Anam, Guro, and Ansan hospitals, which are clinical research test beds, and Jeongneung MediScience Park and Cheongdam Goyeong Campus, which are built with cutting-edge infrastructure. “We want to lead future medicine that advances the health and happiness of humanity by creating a ‘Dream R&D Universe (KU Medicine Research and Development Universe)’ centered around Korea University Medical Center,” he said.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.